title: An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.
abstract: Spencer Phillips Hey and Aaron Kesselheim propose that informativeness-asserting scientific facts-rather than truthfulness ought to be the standard for regulating commercial speech about pharmaceuticals.
authors.affiliation: The Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.|The Harvard Center for Bioethics, Harvard Medical School, Boston, Massachusetts, United States of America.
authors.forename: Spencer Phillips
authors.initials: SP
authors.lastname: Hey
authors.affiliation: The Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.|The Harvard Center for Bioethics, Harvard Medical School, Boston, Massachusetts, United States of America.
authors.forename: Aaron S
authors.initials: AS
authors.lastname: Kesselheim
mesh_terms: D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007603:Jurisprudence; D040541:Marketing / Q000331:legislation & jurisprudence*; D056687:Off-Label Use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000960:Hypolipidemic Agents; C035276:eicosapentaenoic acid ethyl ester; D015118:Eicosapentaenoic Acid